Valerie Daggett
February 29, 2024
Q&A: How a potential treatment for Alzheimer’s disease could also work for Type 2 diabetes
Alzheimer’s disease and Type 2 diabetes are part of a family of amyloid diseases that are characterized by having proteins that cluster together. UW researchers have demonstrated more similarities between the two diseases.
December 5, 2022
New blood test can detect ‘toxic’ protein years before Alzheimer’s symptoms emerge, study shows
Researchers at the University of Washington have detected “toxic” small aggregates of a particular protein in the blood of individuals with Alzheimer’s disease, as well as in individuals who showed no signs of cognitive impairment at the time the blood sample was taken, but who developed it at a later date. This blood test picks up oligomers — or small, misfolded aggregates — of the amyloid beta protein, which scientists believe triggers the development of Alzheimer’s.
October 10, 2022
Engineering lecture series focuses on health care for the brain
The University of Washington’s annual Engineering Lecture Series will feature research with potential to transform brain therapeutics from infancy to late adulthood.
April 15, 2019
Synthetic peptide can inhibit toxicity, aggregation of protein in Alzheimer’s disease, researchers show
A team led by researchers at the University of Washington has developed synthetic peptides that target and inhibit the small, toxic protein aggregates that are thought to trigger Alzheimer’s disease.
July 28, 2014
New protein structure could help treat Alzheimer’s, related diseases
University of Washington bioengineers have a designed a peptide structure that can stop the harmful changes of the body’s normal proteins into a state that’s linked to widespread diseases such as Alzheimer’s, Parkinson’s, heart disease, Type 2 diabetes and Lou Gehrig’s disease.